Hinova Pharmaceuticals Inc. A (688302) fair value: what the stock is really worth
As of Oct 30, 2026: fair value (intrinsic value) of Hinova Pharmaceuticals Inc. A stock ¥6.67, price ¥30.46, upside -78.1%, quality 53 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Oct 30, 2026.
How to read this chart
55‑month range ¥23.17 – ¥74.97 · fair‑value band ¥4.40 – ¥8.33 · the ¥30.46 price screens above the ¥6.67 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Oct 30, 2026.
Follow Hinova Pharmaceuticals Inc. A in your weekly email
Every Wednesday you see whether Hinova Pharmaceuticals Inc. A is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Hinova Pharmaceuticals Inc., a clinical-stage pharmaceutical company, engages in the development and production of therapeutics for cancers and metabolic syndromes. It develops drugs based on proteolysis targeting chimera and deuteration technology.
Show moreShow less
The company's products pipeline includes HC-1119, a product in phase III clinical trials with castration resistant prostate cancer indications; HP501, a product in phase II clinical trials for the treatment of hyperuricemia and gout; HP558, a product in phase II clinical trials to treat various late-stage cancers; and HP518, an oral PROTAC drug in phase I clinical trials with a focus on to solve the drug resistance of AR-mutated prostate cancer.
Hinova Pharmaceuticals Inc. was founded in 2013 and is headquartered in Chengdu, China.
Stock analysis
Hinova Pharmaceuticals Inc. A (688302) currently trades at ¥30.46, while our model-based Fair Value estimate is ¥6.67, 78.1% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the data coverage at low.
Scenario range: ¥4.40 (bear) to ¥8.33 (bull), the price of ¥30.46 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 53/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Hinova Pharmaceuticals Inc. A reported revenue of 20.5M CNY in FY2025 versus 0 CNY in FY2021. Reported net income was −137M CNY in FY2025.
Key figures
Market cap 3.0B CNY (≈ $453M) Small · P/S ratio 48.4 · EPS (TTM) ¥−1.27 · Dividend yield 0.0% · Return on equity −12.3% · Return on assets (EBIT) −20.7% · Operating margin −122% · Revenue growth (YoY) +120%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 6 out of 100 (low confidence).
What moves the price
The share trades about 47% below its 52-week high and 10% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −78%, 688302 screens richer than that median.
Fair Value models
Bear¥4.40Fair Value ¥6.67Bull¥8.33
Price ¥30.46 · Upside -78.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.25/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+5,480.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+131.5%
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+30.1%
’19
’22
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−2,638.9% (2019) → −768.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Hinova Pharmaceuticals Inc. A with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 588 stocks
Beats the industry median on 3/9 measures
Overall it trails its industry peers.
Valuation
Quality Score53 · Above median
Fair Value upside−78.1% · Bottom 25%
Profitability
Return on assets−10.5% · Above median
Operating margin (12 months)−122.1% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)119.8% · Top 25%
Dividend yield (12 months)0.0% · Bottom 25%
Balance sheet
Debt / equity0.09× · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B2.84× · Pricier than median
P/S (12 months)48.43× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)100· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)95· sector 97
DIVIDEND (yield)1· sector 23
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Hinova Pharmaceuticals Inc. A Fair Value". https://www.fairvalue-calculator.com/stock/688302
Frequently asked questions
Is Hinova Pharmaceuticals Inc. A (688302) overvalued or undervalued?
As of Oct 30, 2026, our model estimates a fair value of ¥6.67 versus a price of ¥30.46, about −78% upside (overvalued).
What is the fair value of 688302?
Our model-based fair value for Hinova Pharmaceuticals Inc. A is ¥6.67 (as of Oct 30, 2026), built from audited fundamentals. The current price: ¥30.46.
What is the quality score of 688302?
Hinova Pharmaceuticals Inc. A has a Quality Score of 53/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Hinova Pharmaceuticals Inc. A (688302)?
Our model-based price target is the fair value of ¥6.67 (as of Oct 30, 2026) from 1 valuation models. Cautious scenario ¥4.40, optimistic scenario ¥8.33. It is a calculation from audited fundamentals, not an analyst target.
What is the Hinova Pharmaceuticals Inc. A stock forecast for 2026?
Our models put fair value at ¥6.67, about −78% upside versus a price of ¥30.46 (overvalued). Cautious scenario ¥4.40, optimistic scenario ¥8.33. The calculation is refreshed regularly with new filings.
Does Hinova Pharmaceuticals Inc. A pay a dividend?
Hinova Pharmaceuticals Inc. A currently shows a dividend yield of 0.04% relative to its recent price (as of Oct 30, 2026).
What is the intrinsic value of Hinova Pharmaceuticals Inc. A (688302)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Hinova Pharmaceuticals Inc. A it is ¥6.67 per share (as of Oct 30, 2026), against a price of ¥30.46. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Hinova Pharmaceuticals Inc. A stock overvalued or undervalued in 2026?
As of Oct 30, 2026, 688302 trades above its calculated fair value: price ¥30.46, fair value ¥6.67, a gap of about −78% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 688302?
No. The price is what the market pays today (¥30.46); the fair value is what the company's own numbers justify (¥6.67). For Hinova Pharmaceuticals Inc. A the two are ¥23.79 per share apart. That gap is exactly why we show both numbers side by side.
How much is Hinova Pharmaceuticals Inc. A worth?
The market values Hinova Pharmaceuticals Inc. A at about 3.0B CNY (market capitalisation, as of Oct 30, 2026). Per share that is ¥30.46; our models calculate a fair value of ¥6.67 per share.
What do the bullish and bearish scenarios say about 688302?
Our models span a range for Hinova Pharmaceuticals Inc. A: cautious scenario ¥4.40, base ¥6.67, optimistic ¥8.33 per share (as of Oct 30, 2026, price ¥30.46). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Hinova Pharmaceuticals Inc. A (688302)?
Balance-sheet figures for Hinova Pharmaceuticals Inc. A (as of Oct 30, 2026): return on equity −12.3%, debt of 0.09 per unit of equity. They feed the Quality Score of 53/100, which measures business quality independently of the share price.
How far is 688302 from its 52-week high?
Hinova Pharmaceuticals Inc. A trades at ¥30.46, about 47% below its 52-week high of ¥57.00 and 10% above the low of ¥27.68 (as of Oct 30, 2026). Distance from the high says nothing about value: that is what the fair value of ¥6.67 is for.
Which stocks are comparable to Hinova Pharmaceuticals Inc. A?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Hinova Pharmaceuticals Inc. A stock attractive at the current price?
The data as of Oct 30, 2026: price ¥30.46, calculated fair value ¥6.67 (−78%), Quality Score 53/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 688302 calculated?
We run Hinova Pharmaceuticals Inc. A through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥6.67, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.4 % above its aggregate fair value. Hinova Pharmaceuticals Inc. A itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Hinova Pharmaceuticals Inc. A (688302)?
The closing price on Oct 30, 2026 was ¥30.46. Our model-based fair value is ¥6.67, about −78% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Hinova Pharmaceuticals Inc. A right now?
The price sits above even our optimistic bull case (¥8.33). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (53/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (¥4.40 to ¥8.33) leaves room in how you read the outcome.
Key figures of Hinova Pharmaceuticals Inc. A
How large is the market capitalisation of Hinova Pharmaceuticals Inc. A (688302)?
The market capitalisation of Hinova Pharmaceuticals Inc. A is 3.0B CNY (≈ $453M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Hinova Pharmaceuticals Inc. A (688302)?
The price-to-sales ratio of Hinova Pharmaceuticals Inc. A is 48.4 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Hinova Pharmaceuticals Inc. A (688302)?
Earnings per share at Hinova Pharmaceuticals Inc. A are ¥−1.27. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Hinova Pharmaceuticals Inc. A (688302)?
The dividend yield of Hinova Pharmaceuticals Inc. A is 0.0%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the return on equity of Hinova Pharmaceuticals Inc. A (688302)?
The return on equity (ROE) of Hinova Pharmaceuticals Inc. A is −12.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Hinova Pharmaceuticals Inc. A (688302)?
On an EBIT basis the return on assets of Hinova Pharmaceuticals Inc. A is −20.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Hinova Pharmaceuticals Inc. A (688302)?
The operating margin of Hinova Pharmaceuticals Inc. A is −122% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Hinova Pharmaceuticals Inc. A (688302)?
Revenue at Hinova Pharmaceuticals Inc. A is growing +120% versus a year earlier (3y avg +131%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Hinova Pharmaceuticals Inc. A (688302) generate?
The free cash flow of Hinova Pharmaceuticals Inc. A is −192M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed
Watch Hinova Pharmaceuticals Inc. A in the live analysis
One click puts Hinova Pharmaceuticals Inc. A on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Thin data
Oct 30, 2026